Molecular Partners to Present at the Morgan Stanley Global Healthcare Conference in New York

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / September 7, 2017 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today announced that Dr. Patrick Amstutz, CEO of Molecular Partners, and Andreas Emmenegger, CFO, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2017 at 4:40 PM Eastern Time (10:40 PM CET).

The presentation will be available for viewing via live webcast and can be accessed on the day through this link. A replay of the webcast will be made available on the company’s website, www.molecularpartners.com, under the Investors section. The replay will be available for 180 days following the presentation.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies. With a management team that includes many of the founding scientists, the company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Dr. Patrick Amstutz, acting CEO
patrick.amstutz@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Andreas.Emmenegger, CFO
andreas.emmenegger@molecularpartners.com

Tel: +41 (0) 44 755 77 00

Rolf Schläpfer
Hirzel.Neef.Schmid.Counselors
rolf.schlaepfer@konsulenten.ch
Tel: +41 (0) 43 344 42 42

Susan A. Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
Tel: +1 212 966 3650

SOURCE: Molecular Partners AG

ReleaseID: 474691